Nanobiotix announced positive one-year survival and progression-free survival rates from its Phase 1 trial of JNJ-1900 (NBTXR3) in NSCLC patients. This data suggests the drug's potential for clinically meaningful local control with lower re-irradiation doses, indicating a significant step forward in its development.
Nanobiotix reported encouraging one-year data from its Phase 1 trial of JNJ-1900 (NBTXR3) for non-small cell lung cancer (NSCLC). The drug demonstrated a 61% one-year local progression-free survival and 70% one-year overall survival, achieved with a lower re-irradiation dose than standard treatment. This is a significant positive for Nanobiotix as it validates the potential of their lead candidate and could lead to further clinical development and eventual market approval. For traders, this news presents a short-term opportunity for NBTX due to increased investor confidence, and a long-term opportunity if subsequent trials continue to show positive results, potentially impacting the NSCLC treatment landscape. The partnership with Johnson & Johnson (JNJ) also adds credibility and resources to the program.